Major U.S. Pfizer Brands

Other Major U.S. Brands 

Pfizer’s Lyrica (seizures/nerve pain, on U.S. market since 2004)

• 2005 Reported U.S. Sales: $717 million
• 2017 Reported U.S. Sales: $3.5 billion
• 2017 U.S. Sales WITHOUT Price Increases: $1.16 billion
• Cumulative harm since start of Part D: $10.0+ billion

Other major U.S. Pfizer brands:

• Strong U.S. sales growth driven by severe prices increases
  • As clinical use sharply declined
• Premarin (hormone replacement)
• Viagra: (impotence)
• Celebrex (arthritis, pain)
• Chantix (smoking cessation)
• Link to U.S. Pfizer severe price increase and declining prescription trends
• Link to the summary of U.S. sales and "pharma fee" abuse from the Southern District of New York (SDNY) whistleblower case, including key Pfizer U.S. brands